[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
February 1994

Does Wavelength Matter When Photocoagulating Eyes With Macular Degeneration or Diabetic Retinopathy?-Reply

Arch Ophthalmol. 1994;112(2):157. doi:10.1001/archopht.1994.01090140030010

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In reply  The preliminary work by Brancato and colleagues on the clinical efficacy of diode laser panretinal photocoagulation in eyes with proliferative diabetic retinopathy is duly noted. Unfortunately, the sample size required to evaluate a treatment difference between panretinal photocoagulation performed with argon green vs diode laser is far greater than that which appears in published reports. Thus, it is not yet possible to conclude that the two laser wavelengths provide comparable treatment benefits with equivalent risks. In fact, the work of Brancato and colleagues suggests that diode laser panretinal photocoagulation produces greater patient discomfort, requires more laser sessions to place the treatment, precipitates choroidal detachments, and produces more confluent chorioretinal atrophy than is customarily encountered with argon panretinal photocoagulation. Certainly, a larger-scale and longer-term study is needed to reliably evaluate these issues.

First Page Preview View Large
First page PDF preview
First page PDF preview